The CheckMate 025 study comparing nivolumab with everolimus in mRCC patients previously treated with anti-VEGF TKIs showed superiority of nivolumab and has been used as monotherapy in advanced RCC patients who progressed after prior antiangiogenic therapy [8]. Here, VEGFA is linked to renal cell adenocarcinoma.